Vertex Pharmaceuticals Incorporated (VRTX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
VRTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
VRTX Revenue Analysis (2014–2025)
As of February 28, 2026, Vertex Pharmaceuticals Incorporated (VRTX) generated trailing twelve-month (TTM) revenue of $11.72 billion, reflecting strong growth of +11.0% year-over-year. The most recent quarter (Q3 2025) recorded $3.08 billion in revenue, up 3.8% sequentially.
Looking at the longer-term picture, VRTX's 5-year compound annual growth rate (CAGR) stands at +14.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $12.00 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows VRTX's business is primarily driven by TRIKAFTA/KAFTRIO (86%), ALYFTREK (7%), and Manufactured Product, Other (7%). With over half of revenue concentrated in TRIKAFTA/KAFTRIO, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), ASND (+97.4% YoY), and BBIO (+126.3% YoY), VRTX has underperformed the peer group in terms of revenue growth. Compare VRTX vs AGIO →
Peer Comparison
Compare VRTX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VRTXCurrent | $11.7B | +11.0% | +14.1% | 39.1% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% | |
| PTCT | $1.7B | +97.5% | +35.4% | 50.1% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $12.00B | +8.9% | $10.35B | 86.2% | $4.69B | 39.1% |
| 2024 | $11.02B | +11.7% | $9.49B | 86.1% | $-232,900,000 | -2.1% |
| 2023 | $9.87B | +10.5% | $8.61B | 87.2% | $3.83B | 38.8% |
| 2022 | $8.93B | +17.9% | $7.85B | 87.9% | $4.31B | 48.2% |
| 2021 | $7.57B | +22.1% | $6.67B | 88.1% | $2.78B | 36.7% |
| 2020 | $6.21B | +49.1% | $5.47B | 88.1% | $2.86B | 46.0% |
| 2019 | $4.16B | +36.6% | $3.62B | 86.8% | $1.20B | 28.8% |
| 2018 | $3.05B | +22.5% | $2.64B | 86.6% | $635.1M | 20.8% |
| 2017 | $2.49B | +46.2% | $2.21B | 88.9% | $123.2M | 5.0% |
| 2016 | $1.70B | +64.9% | $1.49B | 87.6% | $9.9M | 0.6% |
See VRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VRTX vs AGIO
See how VRTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is VRTX's revenue growth accelerating or slowing?
VRTX maintains +11.0% revenue growth, in line with its 5-year CAGR of +14.1%. TTM revenue stands at $11.7B. Growth rate remains consistent with historical average.
What is VRTX's long-term revenue growth rate?
Vertex Pharmaceuticals Incorporated's 5-year revenue CAGR of +14.1% reflects the sustained expansion pattern. Current YoY growth of +11.0% is near this long-term average.
How is VRTX's revenue distributed by segment?
VRTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.